Foundation Medicine Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (2010)
Status: Acquired by Roche (2015)

Organization Overview

First Clinical Trial
2011
NCT01482715
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Flatiron Health, Inc.; Foundation Medicine, Inc. | Foundation Medicine | Foundation Medicine, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Endometrioid (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Cystadenocarcinoma, Serous (Phase 2)

Endometrial Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Hypersensitivity (Phase 2)

Neoplasms, Unknown Primary (Phase 2)

Neuroblastoma (Phase 1)

Ovarian Neoplasms (Phase 3)

Peritoneal Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 37